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ABSTRACT 
 
 Cystic fibrosis (CF) is one of the most prevalent fatal autosomal recessive 
diseases in the United States. Although early diagnosis and improved treatment 
methods have helped increase the median predicted survival age of CF patients, 
CF remains a burdensome and life-threatening disease. Furthermore, the 
challenges of treating CF are amplified by the fact that there are over 1,800 
known CF mutations. 
 Recent advances in drug therapy have begun to target the main classes of 
CF mutations at the protein level, addressing mutational events instead of 
downstream disease processes. Three drugs, including ivacaftor, which has 
been approved by the United States Food and Drug Administration, and VX-809 
and ataluren, which are still in clinical trial, have been shown to improve patient 
clinical measures. VX-809 targets the most prevalent CF mutation, F508del, and 
used in combination with ivacaftor was shown to significantly decrease mean 
sweat chloride concentrations and significantly increase forced expiratory volume 
in one second, an indicator of lung function. Almost 89 percent of people with CF 
have at least one copy of the F508del mutation and about 47 percent are 
v 
homozygous for F508del, while ivacaftor is approved for use in only four percent 
of the CF population. For these reasons, if approved, use of VX-809 in 
combination with ivacaftor has the potential to benefit far more patients than 
ivacaftor ever could alone. 
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I. INTRODUCTION 
 
 Cystic fibrosis (CF) is one of the most common fatal autosomal recessive 
diseases with an estimated prevalence of 30,000 cases in the United States 
(Farrell et al., 2008). CF affects all races and ethnic groups but its incidence is 
higher among Caucasian populations at about 1 in 3,500 (Cystic Fibrosis 
Foundation (CFF), 2011; CFF, 2012) compared to African American (1 in 15,000) 
(Hamosh et al., 1998), Asian (1 in 32,000) (Imalzumi, 1995), or Hispanic (1 in 
9,000) (Grebe, Seltzer, DeMarchi, Silva, & Doane, 1994) populations. CF is 
caused by the build up of thick mucus that can clog multiple organs in the body, 
including the lungs and digestive system, which leads to persistent infections, 
inflammation and swelling, organ damage, and decreased organ function (CFF, 
2011; CFF, 2012). While only five states required CF newborn screening (NBS) 
in 2005, the 50 states and the District of Columbia passed legislation in 2009, 
mandating that by year 2010, all newborns be screened for CF (CFF, 2011; CFF, 
2012). This mandate helped increase the likelihood of early diagnosis of CF 
(Figure 1) (Welsh, 2010). Early diagnosis is critical to improve patient outcomes, 
likely due to the fact that it allows treatment to commence sooner (Farrell et al., 
2008; CFF, 2011; CFF, 2012; Welsh, 2010). 
 This paper will provide relevant background information on CF, current 
diagnostic procedures, and therapies that treat the downstream disease 
processes. The main discussion will offer a review of exciting new and potential 
drug therapies that will bring a personalized approach to CF treatment.  
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Figure 1. Percent of CF cases detected by NBS from 1990-2010. In 2005, five 
states mandated CF NBS. In 2009, all 50 states and the District of Columbia 
passed legislation to mandate CF NBS by 2010. More than half of the CF cases 
were detected through NBS in 2010 (Figure from CFF, 2011). 
 
 
A. Genetics 
In the early 1980s, CF was determined to be a physiological defect in cyclic 
adenosine monophosphate (cAMP) regulated chloride transport (Knowles, Gatzy, 
& Boucher, 1981; Knowles et al., 1983; Knowles, Gatzy, & Boucher, 1983; 
Quinton, 1983). Chloride (Cl-) permeability was greatly reduced in subjects with 
CF, which resulted in high nasal mucosa and bronchi transepithelial electrical 
potential differences (PD) (Knowles, Gatzy, & Boucher, 1983). In addition, this 
reduced Cl- permeability in CF patients lead to poor reabsorption of sodium 
chloride (NaCl) in the sweat duct, and therefore a high concentration of NaCl in 
sweat of these patients, leading to a slightly salty skin surface (Quinton, 1983). 
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Furthermore, Quinton (1983) attributed the increased transepithelial electrical PD 
in CF patients to the separation of charge brought about by the difference in 
anion permeability of the tissue. By 1985, it was determined that the CF defect, 
inherited in an autosomal recessive manner, was located on human chromosome 
7 (Tsui et al., 1985). Using positional cloning, Kerem et al. (1989), Riordan et al. 
(1989), and Rommens et al. (1989) showed that CF is caused by mutations that 
occur in region q31, a single gene region, on the long (q) arm of human 
chromosome 7. The CF gene was shown to span 250 kilobases and encode a 
1,480 amino acid protein (Kerem et al., 1989; Riordan et al., 1989; Rommens et 
al., 1989). The CF gene product is known as the cystic fibrosis transmembrane 
conductance regulator (CFTR). 
 The CFTR protein is comprised of two repeated motifs (Figure 2). Each 
motif has six hydrophobic transmembrane segments and a nucleotide binding 
fold (NBF) and the two repeats are separated by a large, polar, R-domain which 
has 69 alternating positively and negatively charged amino acids and multiple 
potential sites for protein kinase A (PKA) phosphorylation (Cheng et al., 1990; 
Kerem et al., 1989; Li et al., 1996; Riordan et al., 1989). The CFTR protein 
undergoes glycosylation before it is inserted into the cell membrane, so it is 
therefore a membrane-associated glycoprotein in its mature form (Cheng et al., 
1990; Kerem et al., 1989). 
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Figure 2. The CFTR gene and its protein product. The CFTR gene is located on 
the long arm of region 31 on human chromosome 7. It contains 27 exons that 
encode the CFTR protein (1,480 amino acids). The mature protein is 
glycosylated and contains two repeated motifs, each with six transmembrane 
segments and a NBF, which are separated by the R-domain. The R-domain has 
charged amino acid residues and numerous phosphorylation sites (Figure from 
Gibson, Burns, & Ramsey, 2003). 
 
 B. CFTR 
The CFTR protein is a cAMP-regulated Cl- channel that is not activated by 
membrane depolarization (Berger et al., 1991). In epithelia with wild-type CFTR, 
an increase in cellular cAMP reversibly activates low conductance Cl- channels, 
while it fails to open apical membrane Cl- channels in CF cell (Berger et al., 
1991). Generally speaking, cAMP activates the tetrameric holoenzyme PKA by 
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binding its two regulatory subunits, which releases its two catalytic subunits 
(Zhang et al., 2012). The PKA catalytic units can then use adenosine 
triphosphate (ATP) to phosphorylate serine or threonine residues on a given 
protein. Both PKA and hydrolysis of ATP are required for normal channel gating 
(Berger et al., 1991; Li et al., 1996; Riordan et al., 1989). Evidence suggests that 
the CFTR has intrinsic ATPase activity that is coupled to its gating activity: (1) 
both ATPase activity and channel gating are regulated by PKA phosphorylation; 
(2) PKA phosphorylation enhances CFTR ATPase activity by increasing affinity 
for ATP; (3) the phosphorylated R domain may coordinate the activities of the 
two NBF of CFTR; (4) the rate of ATP turnover and channel gating by 
phosphorylation are similar, which suggest that the activities are coupled (Li et 
al., 1996). In the opened state, Cl- is transported across the epithelial cell 
membrane. 
 
 C. CFTR Mutations 
There are more than 1,800 known CF mutations, however, a single mutational 
event, F508del, a three base-pair deletion in the CF gene resulting in the loss of 
a phenylalanine residue at position 508, accounts for the majority of CF 
mutations (Table 1) (Cheng et al., 1990; Kerem et al., 1989; CFF, 2011; CFF, 
2012). According to the Cystic Fibrosis Foundation (CFF) Patient Registry 
(2011), almost 89 percent of people with CF have at least one copy of the 
F508del mutation, and about 47 percent have two copies. 
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Table 1. Common CF mutations in 2010. F508del is by far the most common 
mutation of the CFTR gene (Table amended from CFF, 2011). 
 
Mutation Percentage (%) of People with CF 
with at Least One Mutation 
F508del 88.5 
G542X 4.6 
G551D 4.4 
R117H 2.7 
N1303K 2.5 
W1282X 2.4 
R553X 1.9 
 
 
 
 
The next three most prevalent CF mutations include G542X (a glycine to 
threonine missense mutation at amino acid position 542 resulting in a stop 
codon), G551D (a glycine to aspartate missense mutation at amino acid position 
551), and R117H (an arginine to histidine mutation at residue 117) (Comer et al., 
2009; CFF, 2012). These mutations can be further classified into Class I thru 
Class VI mutations (Figure 3, Table 2).  
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Figure 3. General classification of CFTR mutations (Figure from Hull, 2012). 
 
 
 
 
 
Table 2. Classes of CFTR mutations and their consequences (Table from Bush  
& Simmonds, 2012). 
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F508del is a Class II mutation; a structural alteration prevents maturation 
of the carbohydrate in the Golgi, so the protein becomes trapped in the 
endoplasmic reticulum (ER) where it is degraded or transported to lysosomes for 
degradation (Cheng et al., 1990). Therefore, F508del mutations result in little or 
no CFTR reaching the apical membrane (Bush & Simmonds, 2012; Cheng et al., 
1990; Hull, 2012; Pettit, 2012). G542X is a Class I mutation resulting in no CFTR 
synthesis due to the premature stop codon (Bush & Simmonds, 2012; Pettit, 
2012). G551D mutations belong to Class III where the channel reaches the 
apical membrane but there is decreased channel opening. This is due to the fact 
that G551D lies within a motif that is conserved in nucleotidases, so a mutation 
here markedly reduces ATPase activity, and therefore channel gating (Li et al., 
1996). The R117H mutation is a Class V mutation where there is a reduction in 
the number of CFTR channels in the apical membrane (Bush & Simmonds, 2012; 
Pettit, 2012). 
 Classic and nonclassic forms of CF directly reflect the number of loss-of-
function CFTR mutations. With classic CF, the patient has two loss-of-function 
mutations, whereas patients with nonclassic CF have a least one copy of a 
mutant gene that confers partial CFTR protein function (Borowitz et al., 2005). 
While heterogeneity exists in the severity of lung disease among these patients, 
nonclassic CF patients generally show a slower overall rate of progression of 
lung disease and have a median survival almost double that of patients with 
classic CF (Borowitz et al., 2005).  
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 The F508del genotype usually results in a poorer clinical phenotype. Adult 
patients with the G551D or R117H mutations tend to have milder clinical 
phenotypes, including a higher body mass index (BMI), less impaired glucose 
tolerance, and fewer chronic infections with Pseudomonas aeruginosa (Comer et 
al., 2009). Furthermore, in a retrospective cohort study comparing standardized 
mortality rates, CF patients heterozygous for F508del had significantly lower 
mortality rates compared to homozygous F508del CF patients (McKone, 
Emerson, Edwards, & Aitken, 2003; McKone, Gross, & Aitken, 2006). 
 
 D. Pathogenesis and Clinical Manifestations 
CFTR expression is known to inhibit the epithelial sodium (Na+) channel (ENaC) 
in epithelial cells, so it was often believed that CF glands had excessive ENaC-
mediated fluid absorption due to ENaC disinhibition in CF glands due to loss of 
CFTR (Joo, Irokawa, Robbins, Wine, 2006). However, Joo et al. (2006) applied 
ENaC inhibitors to epithelial cells and measured single gland mucus secretion 
optically to determine whether secretion was augmented. Results indicated that 
CF glands do not in fact have excessive, ENaC-mediated fluid absorption, but 
that anion-mediated hyposecretion is the primary mechanism responsible for 
defective mucus secretion in CF glands (Joo et al., 2006).  
Mucus clearance plays an essential role in the innate defense 
mechanisms of the immune system and defects in this clearance are generally 
accepted as the main CF pathogenesis. In patients without lung disease, 
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“effective clearance of particles deposited on airway surfaces requires the 
coordinated activities of a two-phase gel system on the airways surface” 
(Boucher, 2007). This two-phase system includes the periciliary layer (PCL), 
which extends from the cell surface the full length of an extended cilium, and the 
mucus layer deposited on top of these cilia; in between is the airway surface 
liquid (ASL), which is water contained between these layers (Figure 4a) 
(Boucher, 2007; Hull, 2012). The gel system creates a low-friction environment 
where the cilia can beat to clear mucus and also provides lubrication to prevent 
the mucus layer from adhering to the cell surface (Boucher, 2007; Hull, 2012). 
Boucher (2007) further explains that a slight upregulation in Na+ absorption and 
decreased Cl- secretion combine to produce ASL dehydration. This dehydration 
collapses the PCL layer and leads to the adhesion of mucus to the airway 
surface (Figure 4b) (Chmiel & Davis, 2003; Hull, 2012). Mucus adhesion is likely 
to initiate airflow obstruction, inflammation, and the chronic infections that are 
common in CF (Boucher, 2007; Chmiel & Davis, 2003). Evidence supports the 
hypothesis that dehydration of the two-phase ASL compartment hinders mucus 
transport in CF lungs.  
First, “observations from air-liquid interface cultures maintained 
under static conditions have demonstrated that normal airway 
epithelia maintain adequate ASL volume on airway surfaces… for 
extended periods of time, whereas CF cultures do not” (Figure 4c) 
(Boucher, 2007).  
 
Second, overexpression of a single ENaC subunit in transgenic mice produced a 
2.5-fold increase in Nat+ absorption and a subsequent depletion of the ASL, 
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leading to mucus obstruction (Boucher, 2007). About 50 percent of these mice 
died within the first 30 days of life due to severe mucus obstruction, while others 
experienced “neutrophilic inflammation mediated by the production of 
proinflammatory cytokines” and persistent bacterial infections (Figure 4d) 
(Boucher, 2007). Third, evidence from human clinical studies suggests ASL 
volume depletion and therapeutic trials with aerosolized hypertonic saline (HS) 
show that both short-term and long-term inhalation of HS increase mucus 
transport and improve overall lung function (Boucher, 2007). 
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Figure 4. Mucus clearance in the lung. (a) Normal airways have a healthy ASL 
volume that is mediated by the net transport of NaCl. (b) Failure to secrete Cl- in 
the CF lung leads to inappropriate water reabsorption. (c) The water layer 
(green) in CF lungs is drastically reduced at t=24 hours. (d) Cilia are fully 
extended in the PCL space in the normal lung but are flattened in the CF lung 
(Figure from Boucher, 2007). 
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 Since mucus cannot be adequately cleared from the CF airway, 
pathogens can grow in the static airway mucus, leading to persistent bacterial 
infections in CF patients (Chmiel & Davis, 2003). Pseudomonas aeruginosa is 
one of the most common bacteria found in the lungs of CF patients, affecting 
approximately 51.2 percent of all patients (approximately 9.8 percent of these 
infections are multi-drug resistant Pseudomonas aeruginosa) (CFF, 2011). Other 
common respiratory infectious agents affecting CF patients include 
Staphylococcus aureus (67.0 percent, including methicillin-resistant strains at 
35.7 percent), Haemophilus influenzae (17.2 percent), Stenotrophomonas 
maltophilia (13.8 percent), Achromobacter xylosoxidans (6.2 percent), and 
Burkholderia cepacia complex (2.5 percent) (CFF, 2011). Pseudomonas likely 
interacts with the dehydrated mucus in the airways of CF patients to form a 
biofilm, an ideal environment for bacterial growth (Boucher, 2007). CF patients 
may be infected throughout their entire life with the same Pseudomonas 
organism that originally infected and colonized their lungs (Boucher, 2007). 
Furthermore, persistent bacterial infections in the intraluminal space evoke a host 
inflammatory response that can cause significant damage to the airways (Joo et 
al., 2006). One such response is the increase in production of host antimicrobial 
and anti-inflammatory proteins, “in addition to proteins involved in the repair of 
bacterial- and inflammation-induced cell damage” (Boucher, 2007). The 
increased number of these proteins may damage airway walls and lead to 
bronchiectasis, irreversible dilation of the bronchi, making the airway easily 
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collapsible and susceptible to airflow obstruction (Figure 5) (Boucher, 2007). 
 
Figure 5. Bronchiectasis. Bronchiectasis in CF leads to dilated bronchi that are 
easily collapsible and allow for mucus impaction. Bronchiectasis is the result of 
damage to the airway due to persistent infection and inflammation, which in turn 
further reduces mucus clearance and causes the cycle to repeat (Figure from 
Gibson et al., 2003). 
 
 While lung disease is a major manifestation of CF, other organs are also 
generally affected (Table 3). The exocrine pancreas is affected in 85-90 percent 
of CF patients and shows the strongest association between genotype and 
phenotype (Meyerholz, Stoltz, Pezzulo, & Welsh, 2010; Borowitz et al., 2005). 
Patients with CF who have normal fat absorption are considered to be pancreatic 
sufficient (Wyllie, 1999). Although their pancreatic functional capacity can vary, 
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pancreatic sufficient patients tend to have residual CFTR function, and therefore, 
a phenotype that prevents them from experiencing complete pancreatic 
destruction (Borowitz et al., 2005). Pancreatic sufficient patients also have 
enough functioning pancreatic tissue remaining to elicit an inflammatory 
response, so 20 percent of them are at risk of developing symptoms of recurrent, 
acute or chronic pancreatitis (Borowitz et al., 2005; Duffield, 1996). 
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Table 3. Phenotypic manifestations of CF (Table amended from Farrell et al., 
2008). 
 
1. Chronic sinopulmonary disease, manifested by: 
 
a. Persistent colonization/infection with typical CF pathogens, including 
Staphylococcus aureus, nontypeable Haemophilus influenzae, mucoid 
and nonmucoid Pseudomonas aeruginosa, Stenotrophomonas 
maltophilia, and Burkholderia cepacia 
 
b. Chronic cough and sputum production 
 
c. Persistent chest radiograph abnormalities (e.g., bronchiectasis, 
atelectasis, infiltrates, hyperinflation) 
 
d. Airway obstruction, manifested by wheezing and air-trapping 
 
e. Nasal polyps; radiographic or CT abnormalities of the paranasal 
sinuses 
 
f. Digital clubbing 
 
2. Gastrointestinal and nutritional abnormalities, including: 
 
a. Intestinal: meconium ileus, distal intestinal obstruction syndrome, rectal 
prolapse 
 
b. Pancreatic: PI, recurrent acute pancreatitis, chronic pancreatitis, 
pancreatic abnormalities on imaging 
 
c. Hepatic: prolonged neonatal jaundice, chronic hepatic disease 
manifested by clinical or histological evidence of focal biliary cirrhosis 
or multilobular cirrhosis 
 
d. Nutritional: failure to thrive (protein-calorie malnutrition), 
hypoproteinemia and edema, complications secondary to fat-soluble 
vitamin deficiencies 
 
3. Salt loss syndromes: acute salt depletion, chronic metabolic alkalosis 
 
4. Genital abnormalities in males, resulting in obstructive azoospermia 
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Pancreatic insufficiency (PI) develops when more than 90 percent of the 
acinar mass is gone and almost always occurs when loss-of-function mutations 
are present on both alleles (Borowitz et al., 2005; Duffield, 1996; Wyllie 1999). In 
most instances, pancreatic obstructive destruction begins in utero; the acini are 
replaced with fibrous tissue and fat, so functional loss of the exocrine pancreas 
develops at birth or shortly after (Borowitz et al., 2005; Duffield, 1996). As a 
result of this damage, 
“pancreatic secretion of digestive enzymes and bicarbonate is 
disrupted resulting in malabsorption of fat, protein, nitrogen, bile, fat 
soluble vitamins, and vitamin B12” (Duffield, 1996). 
 
This leads to calorie loss, hypoproteinemia, loss of subcutaneous fat, decreased 
muscle mass, and failure to thrive within the first few months of life (Wyllie, 
1999). As pancreatic fibrosis continues, the pancreatic islet cells are destroyed, 
which leads to glucose intolerance in approximately 30 percent of CF patients 
and diabetes mellitus in one to two percent of CF patients (Duffield, 1996). 
Before the widespread use of CF NBS, many infants were diagnosed with 
CF after presenting with meconium ileus, a “neonatal bowel obstruction due to 
inspissated meconium, which occurs almost exclusively in children with CF” 
(Wyllie, 1999). Meconium ileus may be one of the first clinical manifestations of 
CF and occurs in approximately 15 to 20 percent of infants with classic CF within 
the first two days of life (Borowitz et al., 2005; Duffield, 1996; Meyerholz et al., 
2010; Wyllie, 1999). 
Rectal prolapse may occur in up to 20 percent of CF patients and is most 
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common in PI patients (Duffield, 1996; Wyllie, 1999). Prolapse starts between 
two and three years of age and generally only involves the mucosa, so it can be 
replaced by hand (Duffield, 1996). 
CF patients may also present with constipation and distal intestinal 
obstructive syndrome (DIOS). DIOS describes partial or complete intestinal 
obstruction that occurs when “solid or semisolid material accumulates in the 
ileocecal valve where stool is normally liquid” (Duffield, 1996). DIOS may present 
acutely, with abdominal distention, vomiting, and other signs of intestinal 
obstruction, or chronically as colicky abdominal pain and anorexia (Wyllie, 1999). 
DIOS first occurs between childhood and adolescence and recurrence through 
adulthood is common (Duffield, 1996). 
Since CF patients are living longer, hepatobiliary involvement is now seen 
in most patients and liver disease peaks between 16 and 20 years of age and 
has become the second leading cause of death in CF patients (Borowitz et al., 
2005; Meyerholz et al., 2010). In general, the hepatocytes of the parenchyma 
remain healthy while the bile ducts and portal tracts become plugged with thick 
secretions because of decreased CFTR function in biliary epithelium (Duffield, 
1996; Wyllie, 1999). Although liver function tests may remain normal, biliary 
fibrosis progresses due to continued biliary proliferation, cellular infiltration, and 
subsequent inflammation (Duffield, 1996; Meyerholz et al., 2010; Wyllie, 1999). 
This focal biliary cirrhosis (FBC) may develop into bridging or multilobular 
cirrhosis in five to 15 percent of CF patients, leading to portal hypertension and 
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splenomegaly (Borowitz et al., 2005; Duffield, 1996; Meyerholz et al., 2010; 
Wyllie, 1999). Liver transplants have been successful in the majority of these 
patients (Duffield, 1996; Wyllie, 1999). 
Approximately 10 percent of CF patients develop gallstones, which are 
made up of calcium bilirubinate and proteins due to changes in bile acid 
synthesis (Duffield, 1996; Wyllie, 1999). Also common are gallbladder lesions, 
including small gallbladders with hyperplastic epithelium that form mucosal folds 
(cysts) and gallbladders with luminal mucus and thickened bile that result in 
obstruction or stenosis (Meyerholz et al., 2010). 
Fertility of CF patients may also be affected. Approximately 97 percent of 
males with CF are infertile as a result of congenital bilateral absence of the vas 
deferens (CBAVD), which tends to result in obstructive azoospermia (Chan et al., 
2008). Abnormal sperm morphology (teratospermia) and decreased sperm 
motility (oligoasthenospermia) are also common (Chan et al., 2008). The cause 
of female infertility is less conspicuous. While malnutrition can disrupt ovulation 
and cause amenorrhea, it is believed that thickened cervical mucus, with altered 
water and electrolyte concentrations, acts as a barrier to sperm passage (Cha et 
al., 2008). 
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E. Diagnosis 
Before nationwide use of NBS, set criteria, put forth by the CF Foundation, 
had to be met for diagnosis of CF (Table 4) (Davis, Drumm, & Konstan, 1996; 
Rosenstein & Cutting, 1998). 
 
 
Table 4. Diagnostic criteria for CF (Table amended from Davis et al., 1996; 
Rosenstein & Cutting, 1998). 
 
Elevated sweat chloride concentration 
- OR identification of two CF mutations 
- OR demonstration of abnormal nasal epithelial ion transport 
AND one or more phenotypic clinical features (Table 3) 
- OR sibling or first cousin with CF 
- OR positive NBS test result 
 
 
Farrell et al. (2008) recently updated diagnostic recommendations. NBS tests 
measure blood levels of immunoreactive trypsinogen (IRT), however, the 
screening is not a diagnostic test and only identifies those at risk for developing 
CF (Farrell et al., 2008). Since infants with a positive screen do not necessarily 
have clear clinical symptoms, sweat chloride tests are performed in the CF 
diagnostic process for screened newborns (Figure 6) (Farrell et al., 2008). 
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Figure 6. CF NBS diagnostic process. * Sweat tests must be repeated if an 
insufficient sweat quantity is collected. † CF mutations includes CFTR mutant 
alleles known to cause CF disease. ‡ If two CF mutations are in trans, CF may 
still be diagnosed. § Follow the same procedures as above after repeat testing 
(Figure from Farrell et al., 2008). 
 
 
Sweat test reference values vary depending upon age: for infants up to age six 
months, CF unlikely (29 mmol/L), CF possible (30 to 59 mmol/L), indicative of 
CF (60 mmol/L) (Farrell et al., 2008). After six months of age, sweat chloride 
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concentrations of healthy newborns fall, so values are adjusted accordingly: CF 
unlikely (39 mmol/L), CF possible (40 to 59 mmol/L), and indicative of CF (60 
mmol/L) (Farrell et al., 2008). 
Although a diagnosis of CF can be made if the sweat chloride concentration is 
60 mmol/L, either a second sweat chloride test is performed or DNA mutation 
analysis is done to confirm this diagnosis (Farrell et al., 2008). Individuals in the 
intermediate rate usually undergo extensive CFTR mutational analysis to confirm 
a diagnosis (Farrell et al., 2008). Generally, those with sweat chloride values 29 
mmol/L or 39 mmol/L do not have CF, however, there have been cases in which 
individuals with CF maintain normal sweat chloride values (Farrell et al., 2008). In 
any case where sweat chloride values are inconclusive, DNA analysis may be 
useful in making the diagnosis. To be considered a cause of CF, CFTR 
mutations must: 
 “Cause a change in amino acid sequence that severely affects CFTR 
synthesis or function; or 
 Introduce a premature termination signal; or 
 Alter invariant nucleotides of intron splice sites; or 
 Cause a novel amino acid sequence that does not occur in the normal 
CFTR genes from at least 100 carriers of CF mutations from the patient’s 
ethnic group” (Farrell et al., 2008). 
 
However, CF cannot be diagnosed by just the presence of CFTR mutations; the 
mutations must cause significant loss of function and result in a clinical 
phenotype (Farrell et al., 2008). Clinical assessment tests performed to clarify 
diagnosis include growth assessment, lung assessment, exocrine pancreatic 
function tests, respiratory tract cultures for CF-associated pathogens (especially 
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Pseudomonas aeruginosa), liver function tests, and chest radiographs (Farrell et 
al., 2008; Davis et al., 1996; Rosenstein & Cutting, 1998). 
 
 F. Traditional Therapies 
1. Sinuses 
 The bacteria that infect the sinus cavities are similar to those that can 
infect the lungs, including Stapylococcus aureus and Pseudomonas aeruginosa 
(John Hopkins CF Center – Sinus, n.d.). Oral nasal decongestants may help 
reduce congestion, sinus pressure, and nasal passage inflammation, but are only 
recommended for short periods of times, as they can aggravate symptoms (John 
Hopkins CF Center – Sinus, n.d.). 
 A combination of nasal steroids and antibiotics are generally preferred for 
treating sinus symptoms. Inhaled steroids are effective in treating chronic 
sinusitis and can be used for a long durations of time to help reduce sinus 
inflammation (John Hopkins CF Center – Sinus, n.d.). Antibiotics can be used 
when nasal steroids are ineffective. However, length of treatment may extend 
over several weeks and occasionally intravenous antibiotics are necessary (John 
Hopkins CF Center – Sinus, n.d.). 
 Daily saline solution irrigation can also be effective in draining excess 
mucus from the sinuses (John Hopkins CF Center – Sinus, n.d.). Occasionally, 
an antibiotic solution is used to help suppress sinus bacteria since oral and 
intravenous antibiotics may not kill all the bacteria (John Hopkins CF Center – 
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Sinus, n.d.). 
 Sinus surgery is sometimes necessary to drain the infected material, as 
well as remove polyps that can obstruct the airways or even contribute to 
bacterial infections (John Hopkins CF Center – Sinus, n.d.). Unfortunately, 
surgery is not a permanent solution and polyps often recur after removal, so it is 
therefore reserved for those with serious symptoms (John Hopkins CF Center – 
Sinus, n.d.). 
2. Lungs 
 Improving airway clearance is critical for CF patients. A combination of 
mucolytics, which “break down mucus and reduce the thickness of sputum,” and 
chest therapy is often used to improve airway clearance (John Hopkins CF 
Center – Lung, n.d.). Chest therapies, including postural draining, percussion, 
vibration, and coughing, help loosen mucus and can be performed by the patient 
or other caregivers (Table 5) (John Hopkins CF Center – Lung, n.d.). The chest 
therapies are generally performed at least twice daily for 20-40 minutes per 
session and the intensities of these therapies increase when the patient is ill 
(John Hopkins CF Center – Lung, n.d.). 
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Table 5. Chest therapies used to loosen mucus in the lungs of CF patients 
(Table from John Hopkins CF Center – Lung, n.d.). 
 
Postural Draining Patient is places in a downward position 
allowing airway drainage with the aid of 
gravity 
Percussion Clapping on the chest with a cupped hand 
loosens airway secretions. 
Vibration Caregivers create vibrations that shake 
secretions from the walls of the lung. 
Coughing Coughing or deep breathing can loosen 
and expectorate mucus. 
 
 
Mechanical devices can also be used if the patient desires more independence in 
their treatment (Table 6) (John Hopkins CF Center – Lung, n.d.). Breathing 
exercises, upper extremity exercises, jogging, and other sports can further help 
strengthen the chest wall muscles to improve the efficiency of airway mucus 
clearance (John Hopkins CF Center – Lung, n.d.). 
 
 
 
Table 6. Mechanical therapies used to loosen mucus in the lungs of CF patients 
(Table from John Hopkins CF Center – Lung, n.d.). 
 
Positive Expiratory 
Pressure (PEP) Device 
Prevents airway closure, 
increases lung ventilation, helps 
clear mucus from lungs. 
High-Frequency Chest 
Wall Oscillation 
(HFCWO) 
A fitted vest and pneumatic 
compressor delivers therapy to 
the entire chest. 
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The use of nebulized hypertonic saline with inhaled mannitol is believed to 
osmotically draw water into the airway lumen to reconstitute the ASL (Figure 7) 
(Boucher, 2007; Hull, 2012). Both short- and long-term studies with hypertonic 
saline demonstrate that inhalation of this rehydrating agent helps increase mucus 
transport, and therefore improve lung functions (Boucher, 2007; Hull, 2012). 
CF patients with persistent coughing and wheezing are generally put on 
bronchodilators, which relax smooth muscle to dilate the airways, and can help 
prevent or decrease bronchospasm (John Hopkins CF Center – Lung, n.d.). 
Short-acting bronchodilators, including albuterol and levalbuterol, are generally 
used before chest therapy to help drain mucus; long-acting forms are used in 
patients where the therapy has proven to improve lung function in that individual 
(John Hopkins CF Center – Lung, n.d.). 
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Figure 7. The effects of inhalation of hypertonic saline on ASL volume in normal 
(b-d) and CF patients (e-g). (a) Saline (1000 mM) is hypertonic to the interstitium 
(140 mM). (b) In the normal lung, water moves into the airway and ENaC and 
CFTR channels help dissipate the gradient. (c) There is a slight increase in ASL 
volume. (d) Active sodium transport helps gradually reabsorb the additional ASL 
volume. (e) Water moves into the airway, but the NaCl gradient is not dissipated 
due to dysfunctional CFTR. (f) There is a large increase in ASL volume because 
the gradient is not dissipated. (g) Active sodium transport helps gradually 
reabsorb the additional ASL volume, but at t=60 mins, the ASL volume is still 
larger in the CF lung due to the larger initial volume expansion (Figure from 
Boucher, 2007). 
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For CF patients with very poor lung function, lung transplantation is an 
option if they are considered to have a poor prognosis otherwise. After 
successful transplantation, the transplanted lungs will not develop CF, however 
the upper airway and sinuses will still be affected (John Hopkins CF Center – 
Lung, n.d.). Additionally, transplantation requires continued medical attention on 
both the part of the patient and caregivers; the immunosuppressants required to 
prevent transplant rejection also make the patient susceptible to infections (John 
Hopkins CF Center – Lung, n.d.). Five-year survival following lung transplant is 
50 percent and other medical problems can lower this life expectancy (John 
Hopkins CF Center – Lung, n.d.). Given the risks of transplant, and the limited 
number of organs available, this option must be carefully considered by the 
patient and their physician. 
3. Pancreas and Gastrointestinal Tract 
 Pancreatic enzyme supplements are required for cases of decreased 
pancreatic function and pancreatic insufficiency (John Hopkins CF Center – 
Pan/GI, n.d.). The enzyme capsules are enteric coated to prevent enzyme 
inactivation by stomach acids and contain amylase, lipase and protease to break 
down starches, fats, and proteins, respectively (John Hopkins CF Center – 
Pan/GI, n.d.). Enzyme dosage is dependent on severity of disease status and 
body weight (John Hopkins CF Center – Pan/GI, n.d.). 
 Good nutrition and a high calorie diet are essential for CF patients. Due to 
malabsorption, fat-soluble vitamin supplements, including those for vitamins A, D, 
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E, and K, are often recommended for patients (John Hopkins CF Center – 
Pan/GI, n.d.). In addition, a high fat diet (35-40 percent fat) is usually necessary 
to maintain the patient’s weight (John Hopkins CF Center – Pan/GI, n.d.). 
 A side effect of malabsorption is constipation and decreased 
gastrointestinal motility can lead to DIOS, as well as pain and cramping (John 
Hopkins CF Center – Pan/GI, n.d.). Those prone to obstructions usually require 
preventative therapies such as Miralax®, mineral oil, electrolyte solutions, or 
prokinetic agents like metoclopramide (John Hopkins CF Center – Pan/GI, n.d.). 
 PI patients are also at risk of developing CF-related diabetes. Patients 
must therefore regularly monitor their blood sugar throughout the day and use 
insulin therapy to maintain blood sugar following meals (John Hopkins CF Center 
– Pan/GI, n.d.). CF “patients with poorly controlled blood sugars tend to have a 
faster deterioration of lung function, more frequent pulmonary infections, and 
other complications” (John Hopkins CF Center – Pan/GI, n.d.). 
4. Liver 
 Ursodeoxycholic acid can be used to treat CF patients with abnormal liver 
function and often lowers elevated liver function tests (John Hopkins CF Center – 
Liver, n.d.). It acts by promoting bile flow from the liver and decreasing bile duct 
clogging. Patients should also receive hepatitis A and B vaccinations as a 
preventative measure and avoid alcohol and acetaminophen that can damage 
the liver. Fat-soluble vitamin levels should also be closely monitored to ensure 
that supplementation is adequate and that they are not at levels that could 
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compromise liver function (John Hopkins CF Center – Liver, n.d.). 
 CF patients with severe liver disease may need a liver transplant, although 
the best candidates are those with sever liver disease, but only mild lung disease 
(John Hopkins CF Center – Liver, n.d.). Although only 10 CF patients undergo 
liver transplants each year, the five-year survival rate is 75 percent after 
transplantation, which is better than the survival rate of lung transplantation (John 
Hopkins CF Center – Liver, n.d.). 
5. Reproduction 
 In vitro fertilization, in combination with intracytoplasmic sperm injection, 
has improved reproductive success for CF patients. With intracytoplasmic sperm 
injection, a needle is inserted into the epididymis to retrieve sperm (John Hopkins 
CF Center – Reproduction, n.d.). The sperm are then injected into a Petri dish 
containing eggs and if an embryo develops, they are implanted in the female’s 
uterus (John Hopkins CF Center – Reproduction, n.d.). Women with CF are 
usually able to have children as long as they have good nutrition and are not 
suffering from significant lung problems. 
6. Muscle and Bone 
 Exercise and weight bearing movements help to increase bone and 
muscle density in CF patients. Good nutritional status is also critical to preventing 
bone and muscle loss. Calcium and vitamin D supplements, as well as 
bisphosphonates, help promote bone formation during the body’s natural bone 
remodeling process (John Hopkins CF Center – Muscle, n.d.). 
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 G. Current Outlook for CF Patients 
 Early and aggressive CF treatment has dramatically increased the median 
predicted survival age of CF patients (Figure 8). The median predicted survival 
age has increased steadily since the 1980s and is currently 36.8 years (CFF, 
2012). Not only are more CF patients living into adulthood, but they are also 
experiencing improved clinical outcomes such as higher median percent 
predicted forced expiratory volume in 1 second (FEV1) (Figure 9), indicating 
higher lung function, and higher median body mass indices (BMIs) (Figure 10) 
(CFF, 2012). 
 
Figure 8. Median predicted survival of CF patients in five-year increments from 
1987 to 2011 (Figure from CFF, 2012). 
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Figure 9. Median percent predicted FEV1 versus age in 1991, 2001, and 2011 
(Figure from CFF, 2012). 
 
 
Figure 10. Median BMI percentiles versus age in 1991, 2001, and 2011 (Figure 
from CFF, 2012). 
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II. PROGRESS IN CYSTIC FIBROSIS CARE 
 Traditional CF therapies only treat the downstream disease processes that 
are secondary to CFTR loss of function mutations (Van Goor et al., 2009; Welsh, 
2010). Recent advances permit targeting of specific CF mutations, which is 
giving treatment approaches a much more personalized and scientific approach 
(Welsh, 2010). 
 
 A. Ivacaftor 
 CFTR channel gating is tightly regulated and requires phosphorylation of 
the R-domain and subsequent ATP binding and hydrolysis by the nucleotide 
binding domains (NBDs) (Yu et al., 2012; Yu, Kim Chiaw, & Beat, 2011). In vitro 
studies demonstrated that VX-770, also known as ivacaftor (Figure 11), acts as a 
CFTR potentiator to increase CFTR channel open probability in G551D mutated 
cell lines, where normal channel gating activity is impaired (Davis, Yasothan & 
Kirkpatrick, 2012; Eckford, Li, Ramjeesingh, & Bear, 2012; Pyle et al., 2011; Van 
Goor et al., 2009; Yu et al., 2012). 
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Figure 11. The structure and scientific name of ivacaftor (VX-770) (Figure from 
Davis et al., 2012). 
 
A potentiator allows for increased flow of ions through an activated channel, and 
in the case of cultured human CF bronchial epithelia, increased Cl- secretion and 
reduced Na+ and fluid absorption, preventing dehydration of the apical surface 
and allowing for increased cilia beating in culture (Van Goor et al., 2009). 
Ivacaftor is hypothesized to depolarize the apical membrane, reducing the 
electrochemical driving forces for Na+ reabsorption through ENaC, which is 
present in the apical membrane along with CFTR (Van Goor et al., 2009). This is 
supported by the fact that there is a lack of ENaC inhibition by ivacaftor in cells 
that do not express CFTR (Van Goor et al., 2009). However, in order for ivacaftor 
to be effective, CFTR must first be phosphorylated in a PKA-dependent manner 
(via addition of cAMP or PKA to cell cultures), as ivacaftor actives CFTR without 
directly impacting the R-domain (Pyle et al., 2011; Yu et al., 2012). Furthermore, 
the response was more dramatic in G551D/F508del cultures than in F508 del 
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homozygous cultures (Van Goor et al., 2009). 
 Additional studies by Eckford et al. (2012) showed that ivacaftor binds 
directly to the CFTR protein, not associated kinases or phosphatases, and that it 
induces CFTR channel opening via a nonconventional mechanism that is 
independent of ATP binding and hydrolysis. These findings support the idea that 
CFTR can be stimulated by both ATP-dependent and ATP-independent 
mechanisms (Figure 12) (Eckford et al., 2012). Moreover, this explains why the 
drug is effective against the G551D mutation, where the ATP-binding site for 
ATP-dependent gating is disrupted (Eckford et al., 2012). 
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Figure 12. The hypothesized mechanism of action of ivacaftor (VX-770). Only 
the phosphorylated form of CFTR (within the orange rectangle) can be opened in 
an ATP-dependent mechanism (top) or in an ATP-independent mechanism by 
VX-770 (bottom). A closed CFTR channel is shown with a horizontal gate (blue 
bar). The gate is closed when there is no ATP (yellow spheres) in the canonical 
catalytic site between the NBDs. ATP binding causes a NBD dimer to form, 
leading to a conformational change in the loop regions (dark rectangles) and in 
the membrane domains (light rectangles) that opens the gate. VX-770 interaction 
at an unknown site is speculated to cause a conformational change that also 
opens the channel gate and enhances the channel open probability (Figure from 
Eckford et al., 2012). 
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 B. Ivacaftor Clinical Trials 
 Ivacaftor was investigated in humans following the aforementioned in vitro 
studies. Thirty-nine adults with at least one G551D mutation participated in a 
phase II, two-part study testing different doses of ivacaftor to evaluate its safety 
(Appendix 1) (Accurso et al., 2010; Pettit, 2012). Part one of the study compared 
14-day courses of two different doses of ivacaftor, with a washout period in 
between, while part two compared a 28-day course of 150 mg of ivacaftor twice 
daily to a placebo (Accurso et al., 2010). Adverse events, including fever, cough, 
nausea, pain, and rhinorrhea, occurred with similar frequency among all 
treatment groups and the placebo and all adverse events reverted without 
stopping the drug (Accurso et al., 2010; Pettit, 2012). There were statistically 
significant nasal potential differences (NPDs) between baseline values in all 
treatment groups, but the changes were not statistically different from the 
placebo (Accurso et al., 2010; Pettit, 2012). Sweat chloride and FEV1 differences 
from baseline were also statistically significant, but not from the placebo (Accurso 
et al., 2010; Pettit, 2012). The Cystic Fibrosis Questionnaire-Revised (CFQ-R) 
serves as a way to analyze patients’ perceived changes in health-related quality 
of life. Although there were positive changes across all groups, the results were 
not statistically significant from baseline (Accurso et al., 2010; Pettit, 2012). 
 The phase III study, conducted to analyze the efficacy and safety of the 
chosen ivacaftor dose, was performed in CF patients over 12 years old who were 
randomized in either a placebo or treatment group (Appendix 1) (Pettit, 2012; 
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Ramsey et al., 2011). For this study, an ivacaftor dose of 150 mg twice daily was 
chosen since there were no significant increases in outcomes of the 250 mg 
twice daily group compared to the 150 mg twice daily group in the phase II trial 
(Accurso et al., 2010; Pettit, 2012; Ramsey et al., 2011). Results showed a 
statistically significant increase in FEV1, a significant decrease in sweat chloride 
levels, a significant decrease in pulmonary exacerbations, a significant increase 
in weight, and a significant increase in CFQ-R (Pettit, 2012; Ramsey et al., 
2011). Adverse effect occurred more frequently in the ivacaftor group (13 
percent) compared to the placebo group (6 percent) and included upper 
respiratory infection, rash, nasal congestion, headache, dizziness, and 
hypoglycemia (Pettit, 2012; Ramsey et al., 2011). There were also additional 
adverse reactions that required stopping the drug, including high hepatic 
enzymes, atrioventricular block, and respiratory failure (Pettit, 2012; Ramsey et 
al., 2011). Despite these effects, the drug was well tolerated in the majority of 
individuals in the treatment group. 
 Patients from the phase III trial were also given the opportunity to continue 
in an open-label study for two to 60 weeks (McKone et al., 2011; Pettit, 2012). 
Patients in the treatment group maintained their FEV1 and at week 60, 43.5 
percent of patients were free from pulmonary exacerbation (McKone et al., 2011; 
Pettit, 2012). Seventy-six percent of patients experienced adverse effects, 
including cough, hemoptysis, upper respiratory infection, and abdominal pain, but 
only six patients required study drug interruption (McKone et al., 2011; Pettit, 
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2012). The study confirmed that long-term used of ivacaftor has minimal adverse 
effects and that the benefits of therapy are maintained (McKone et al., 2011; 
Pettit, 2012). 
 An additional phase III study was done in CF patients six to 11 years old 
given an ivacaftor dose of 150 mg twice daily for 48 weeks (Appendix 1) (Aherns, 
Rodriguez, Yen, & Davies, 2011; Pettit, 2012). Patients demonstrated a 
statistically significant increase in FEV1, a significant decrease in sweat chloride 
levels, and a significant increase in weight gain, although the mechanism of 
weight gain is unclear (Aherns et al., 2011; Pettit, 2012). 
 Ivacaftor was also studied in patients homozygous for F508del (Appendix 
1). Although the drug was well tolerated, there was no significant change in FEV1 
or sweat chloride levels in compared to the placebo group (Flume et al., 2012; 
Pettit, 2012). This is likely due to the fact that there is a lack of CFTR in the 
apical cell membrane with the F508del mutation (Pettit, 2012). However ivacaftor 
is being considered for use in combination with channel correctors, which will be 
discussed later. 
 
 C. FDA Approval 
The United States Food and Drug Administration (FDA) approved 
ivacaftor (KalydecoTM), the “first-disease modifying therapy approved for CF,” for 
patients six and older who have G551D mutations (FDA, 2012; Ledford, 2012). 
The approved dosage is one 150 mg tablet taken orally twice daily with fat-
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containing food, which help increase absorption of the drug (FDA, 2012; Pettit, 
2012). Ivacaftor dosage is reduced in patients with liver dysfunction or those 
taking cytochrome P450, family 3, subfamily A (CYP3A) inhibitors because 
ivacaftor is primarily metabolized by the CYP3A metabolic pathway (FDA, 2012; 
Hussar & Eckel, 2012). Patient liver function should also be tested every three 
months during the first year of treatment and once per year thereafter (FDA, 
2012). Additionally, ivacaftor may be excreted in breast milk, so caution must be 
used in pregnant or breast-feeing women (FDA, 2012; Pettit, 2012). Although 
patients can use maintenance therapies, it is unclear how these medications will 
interact with ivacaftor or whether they will be needed at all (Pettit, 2012). 
 
D. Limitations of Ivacaftor 
Approximately 1,200 people, about 5 percent of the CF population in the 
US, have the G551D mutation (Bush & Simmonds, 2012; Kaiser, 2012; Ledford, 
2012). In addition to the limited target population, the annual price of ivacaftor is 
very high, $294,000 per year, and could be taken for the patient’s lifetime (Bush 
& Simmonds, 2012; Kaiser, 2012; Ledford, 2012). According to Robert Beall, 
CEO of the CFF, this price is not totally out of line, given that CF is a rare 
disease and the G551D mutation is even rarer (Kaiser, 2012). 
The CFF has invested approximately $75 million into the development of 
ivacaftor and other CF drugs, and although ivacaftor has offered patients 
improved clinical outcomes, it is unclear if this will translate to a survival benefit 
41 
(Beall, 2012; Bush & Simmons, 2012; Ledford, 2012). Nevertheless, CFF has 
royalty rights to ivacaftor and they are working with Vertex Pharmaceuticals to 
make the drug available for CF patients with the G551D mutation (Beall, 2012). 
The plan is to provide the drug free of charge to uninsured patients with 
household incomes below $150,000 and have Vertex cover copayments and 
coinsurance costs up to a total of 30 percent of the drug list price for those with 
insurance (Kaiser, 2012; Pettit, 2012). CFF also plans to use the profits to invest 
back in additional research and development (Beall, 2012). 
 
E. Future Prospects 
Two other CFTR drugs are currently in clinical trial, including VX-809 and 
ataluren (Pettit, 2012). The most common CFTR mutation is F508del, a Class II 
CFTR mutation where the protein is misfolded and retained within the ER (Yu et 
al., 2011). Small molecule correctors have been shown to partially rescue this 
CFTR trafficking defect, 
“allowing a fraction of the mutant protein to escape ER retention 
and traffic to the plasma membrane, where it exhibits partial 
function as a cAMP-regulated chloride channel” (Yu et al., 2011). 
 
VX-809, which binds directly to the mutant protein, is a small molecule corrector 
believed to improve protein conformation so that the protein can become 
functional (Van Goor et al., 2011; Yu et al., 2011). VX-809 has been shown to 
restore F508del-CFTR processing in human bronchial epithelial cells and 
increases chloride secretions by 14 percent (Van Goor et al., 2011). 
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A phase II study looking at the effects of VX-809 alone in CF patients 18 
year and older homozygous for F508del was performed due to the promising in 
vitro results from Van Goor et al. (2011). Patients were randomized into VX-809 
treatment groups, receiving doses of 25, 50, 100, or 200 mg daily, or the placebo 
group for 28 days (Appendix 2) (Clancy et al., 2012; Pettit, 2012). The drug was 
well tolerated; however, there were no significant changes in pulmonary 
exacerbation rate or NPD values (Clancy et al., 2012; Pettit, 2012). There was a 
significant, dose-related decrease in sweat chloride values compared to baseline 
in the 100 mg and 200 mg groups (Clancy et al., 2012; Pettit, 2012). 
Boyle et al., (2011) studied the use of VX-809 in combination with 
ivacaftor in a phase II trial in CF patients over 18 homozygous for F508del 
(Appendix 2). Patients received either 200 mg daily or the placebo for 14 days 
(Boyle et al., 2011; Pettit, 2012). After the fourteenth day, treatment patients 
were given either (1) VX-809 200 mg daily plus VX-770 150 mg twice daily or (2) 
VX-809 200 mg daily plus VX-770 250 mg twice daily, while the placebo group 
continued to receive the placebo (Boyle et al., 2011; Pettit, 2012). There was no 
significant difference in the rate of adverse reactions between the treatment 
groups and placebo but there was a significant difference between the 
combination VX-809 200 mg daily and ivacaftor 250 mg twice daily compared to 
the placebo group (Boyle et al., 2011; Pettit, 2012). Despite the fact that the 
changes in FEV1 were not significant, the study was not adequately powered to 
detect changes in this outcome parameter (Boyle et al., 2011; Pettit, 2012). Due 
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to the fact that there was no concentration plateau in the Clancy et al. (2012) 
study, current studies are evaluating higher doses of VX-809 and ivacaftor 250 
mg twice daily since the combination therapy seems to produce better clinical 
outcomes (Pettit, 2012). 
In 1996, Howard, Frizzel, & Bedwell observed that gentamicin allows 
ribosomes to read right through stop codons. Although CF patients showed 
changes in NPD values following treatment with gentamicin, higher doses were 
needed than were safe to achieve improved chloride function (Clancy et al., 
2011; Pettit; 2012; Wilschanski et al., 2003). PTC 124 (ataluren), like gentamicin, 
also allows ribosomal units to read through mRNA premature stop codons, which 
results in functional protein production, even in CFTR patients with nonsense 
mutations (class I CFTR mutations) (Pettit, 2012; Sermet-Gaudelus et al., 2010). 
Furthermore, the drug does not exhibit harmful side effects at the therapeutic 
dose (Pettit, 2012). 
In a mouse model, ataluren restored chloride concentrations to 24-29 
percent of normal levels in CF mice with G542X mutations (a class I nonsense 
mutation) (Du et al., 2008). A phase I clinical trial in 62 healthy adults looked at 
increasing doses of ataluren, from 3 mg/kg to 200 mg/kg per dose (Hirawat et al., 
2007; Pettit, 2012). Beyond 150 mg/kg, ataluren caused headache, dizziness, 
and gastrointestinal adverse events, but the drug was otherwise well tolerated 
(Hirawar et al., 2007). Pharmacokinetic studies found a time to maximum 
concentration of 1-3 hours and a half-life of 3-6 hours, which increased with 
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increased doses of ataluren; CF patients had similar pharmacokinetic parameters 
to the health adults (Hirawat et al., 2007; Kerem et al., 2008; Pettit, 2012). 
The phase II study conducted by Kerem et al. (2008) looked at the effect 
of two different doses of ataluren given three times daily for 14 days (Appendix 
3). There was an increase in NPD and a slight increase in weight and FEV1, but 
there was no change in sweat chloride levels (Kerem et al., 2008; Pettit, 2012). 
Adverse effects were more prevalent in the higher dosage groups (Kerem et al., 
2008). An extension of this phase II study conducted by Wilschanski et al. (2011) 
studied a high- versus low-dose regimen of ataluren for 12 weeks. There was a 
statistically significant increase in NPDs in both groups and well as increases in 
FEV1 that were not significant (Wilschanski et al., 2011). Moreover, the drug was 
well tolerated and there were no serious adverse events (Pettit, 2012; 
Wilschanski et al., 2011). 
Sermet-Gaudelus et al. (2010) studied a similar dosing regimen in six to 
18 year old children. There were no changes in pulmonary function or BMI, but 
there were significant increases in NPDs and chloride transport (Pettit, 2012; 
Sermet-Gaudelus et al., 2010). Ataluren was also well tolerated with the most 
common adverse event being gastrointestinal symptoms (Pettit, 2012; Sermet-
Gaudelus et al., 2010). 
A phase III, placebo-controlled, study is currently underway to analyze the 
effects of ataluren in CF patients aged six and older (Konstan et al., 2011). 
Patients will receive a dose of 10 mg/kg in the morning, 10 mg/kg midday, and 20 
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mg/kg at night or a placebo for 28 weeks to study the long-term safety and 
efficacy of ataluren (Konstan et al., 2011; Pettit, 2012). 
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III. DISCUSSION AND CONCLUSION 
 CF remains one of the most common fatal autosomal recessive diseases, 
especially in Caucasian populations, and currently affects approximately 30,000 
individuals in the United States (Farrell et al., 2008; CFF, 2012). Mandated NBS 
has helped improve early diagnosis of CF and also allows patients to begin 
treatment sooner (Farrell et al., 2008; CFF, 2011; CFF, 2012; Welsh, 2010). 
Furthermore, early diagnosis and improved treatment methods have helped 
increase the median predicted survival age of CF patients and close to half of all 
living CF patients are over the age of 18 (CFF, 2012). 
 Despite these successes, CF remains a burdensome and life-threatening 
disease. Patients must take numerous medications multiple times each day, 
closely manage their diet to ensure they are receiving adequate nutrition, spend 
hours on chest therapy to improve their lung function, and have frequent and 
recurring sinus and lung infections that require more additional time and energy. 
Unfortunately, traditional CF therapies only target downstream disease 
processes that are secondary to the CFTR mutation. Furthermore, with over 
1,800 known CF mutations, treating the disease at the genetic level can be 
difficult (CFF, 2012). 
 CFTR mutations fall into six main categories: (1) class I mutations, where 
there is no CFTR synthesis, usually due to a premature stop codon; (2) class II 
mutations, where “CFTR is processed incorrectly and does not reach the apical 
cell membrane”; (3) class III mutations where “CFTR reaches the apical 
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membrane, but channel regulation is abnormal” so there is decreased opening; 
(4) class IV mutations, where “CFTR reaches the apical membrane, but channel 
open time is reduced” and ion conductance decreases; (5) class V mutations, 
where there is a reduction in CFTR synthesis; and (6) class VI mutations, where 
“CFTR reaches the apical cell membrane but has a shortened half life due to 
more rapid turnover” (Bush & Simmonds, 2012; Hull, 2012). 
 Recent advances in drug therapy have begun to target these main classes 
of CF mutations, making personalized medicine the future of CF treatment. 
Ivacaftor, a CFTR potentiator that increases CFTR channel open probability, 
allowing for increased ion flow, activates CFTR in an ATP-independent manner 
(Eckford et al., 2012). In a phase III clinical trial with adult CFTR patients, 
ivacaftor was shown to significantly increase FEV1 levels, decrease sweat 
chloride levels, decrease the number of pulmonary exacerbations, increase 
patient weight, and increase patient-reported CFQ-R scores (Pettit, 2012; 
Ramsey et al., 2011). These patients were allowed to continue in an open-label 
study, where they maintained their FEV1 and 43.5 percent of patients were free 
from pulmonary exacerbation at week 60 (McKone et al., 2011; Pettit, 2012). 
Children in a phase III clinical study showed statistically significant increases in 
FEV1, a significant decrease in sweat chloride levels, and a significant increase 
in weight gain (Aherns et al., 2011; Pettit, 2012). 
 In January 2012, ivacaftor was approved for use in CF patients six and 
older who have G551D mutations (FDA, 2012). Although this was a big 
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accomplishment in CF care, there are also some limitations to the drug’s use. 
About 1,200 in the US have the G551D mutation that ivacaftor is indicated for, 
representative of only five percent of the US CF population (Bush & Simmonds, 
2012; Kaiser, 2012; Ledford, 2012). Additionally, ivacaftor’s annual price is 
$294,000 per year per patient and could potentially be taken for the patient’s 
lifetime, making it an extremely costly therapy (Bush & Simmonds, 2012; Kaiser, 
2012; Ledford, 2012). 
Two other CFTR drugs are currently in clinical trial, including VX-809 and 
ataluren (Pettit, 2012). VX-809, which targets the most prevalent F508del 
mutation, is a small molecule corrector believed to improve CFTR protein 
conformation so that the protein can become functional (Van Goor et al., 2011; 
Yu et al., 2011). A phase II study looking at the effects of VX-809 alone in CF 
patients 18 year and older homozygous for F508del found that there was a 
significant, dose-related decrease in sweat chloride values compared to baseline 
in 100 mg and 200 mg treatment groups (Clancy et al., 2012; Pettit, 2012). 
However, there were no significant changes in pulmonary exacerbation rate or 
NPD values (Clancy et al., 2012; Pettit, 2012). 
Boyle et al., (2011) studied the use of VX-809 in combination with 
ivacaftor in a phase II trial in CF patients over 18 homozygous for F508del. There 
was no significant difference in the rate of adverse reactions or FEV1 between the 
treatment groups and placebo but there was a significant difference between the 
combination VX-809 200 mg daily and ivacaftor 250 mg twice daily compared to 
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the placebo group (Boyle et al., 2011; Pettit, 2012). 
Ataluren allows ribosomal units to read through mRNA premature stop 
codons, which results in functional protein production, even in CFTR patients 
with nonsense mutations (class I CFTR mutations) (Pettit, 2012; Sermet-
Gaudelus et al., 2010). The phase II study conducted by Kerem et al. (2008) 
found that there was an increase in NPD and a slight increase in weight and 
FEV1 in treatment groups, but that there was no change in sweat chloride levels 
(Kerem et al., 2008; Pettit, 2012). An extension of this phase II study conducted 
by Wilschanski et al. (2011) studied a high- versus low-dose regimen of ataluren 
for 12 weeks. There was a statistically significant increase in NPDs in both 
groups and well as increases in FEV1 that were not significant (Wilschanski et al., 
2011). Moreover, the drug was well tolerated and there were not serious adverse 
events (Pettit, 2012; Wilschanski et al., 2011). A phase III, placebo-controlled, 
study is currently underway to analyze the effects of ataluren in CF patients aged 
six and older (Konstan et al., 2011). 
 The aforementioned drugs will, and have the potential to, become the 
future of CF treatment given that therapies are becoming tailored to patients’ 
specific CFTR mutations. VX-809 in combination with a twice daily dose of 
ivacaftor seems to hold the most promise for CF care. Although the FDA has not 
yet approved VX-809, human clinical trials have shown a decrease in the number 
of adverse patient reactions and an increase in FEV1 levels in CF patients 
homozygous for F508del when VX-809 is used in combination with ivacaftor 
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(Boyle et al., 2011; Pettit, 2012). Almost 89 percent of people with CF have at 
least one copy of the F508del mutation and about 47 percent are homozygous 
for F508del (CFF, 2011). Looking at homozygous F598del CF patients alone, this 
means that approximately 14,000 individuals could benefit from this combined 
treatment, a ten-fold increase from the G551D population that ivacaftor alone has 
been approved for. This is not to say that attempts to target other classes of the 
CFTR mutation are not warranted, but VX-809 has the potential to positively 
impact the lives of far more patients. 
 Given that the CF population in the US is quite small compared to the total 
population; pharmaceutical prices are bound to be high if the FDA ever approves 
VX-809 or ataluren. It is hopeful that the CFF and sponsoring pharmaceutical 
companies will make similar efforts as they have for ivacaftor to provide future 
drugs to CF patients at reduced costs. These drugs treat the root cause of CF, 
the defective CFTR due to a mutational event. Although it is unclear if drug 
therapy will subsequently improve downstream disease processes to the point of 
few clinical symptoms, personalized medicine has given many CF patients the 
hope of a long-lived and disease-free life. 
 
 
APPENDICES 
  Appendix 1. Ivacaftor (VX-770) studies (Table amended from Pettit, 2012). 
 
Reference Design Treatment Results 
Accurso et 
al., 2010 
Part 1: 
 
Double-blind, 
placebo- 
controlled, 
modified 
crossover 
 
Pts. randomized 
to receive 2 doses 
of VX-770 or 
placebo for two 
14-day periods 
with a 7- to 28-day 
washout period in 
between 
 
 
 
Part 2: 
 
Parallel 39 pts. 
with CF 
Age 18-51 years 
FEV1 >40% 
At least 1 G551D 
 
Pts. randomized 
to 1 of 2 treatment 
regimens or 
placebo for 28 
Part 1: 
 
Group 1 (n = 4) 
-VX-770 25 mg twice 
daily, then VX-770 75 
mg twice daily 
 
Group 2 (n = 4) 
-VX-770 75 mg twice 
daily, then VX-770 25 
mg twice daily 
 
Group 3 (n = 4) 
-VX-770 75 mg twice 
daily, then VX-770 150 
mg twice daily 
 
Group 4 (n = 4) 
-VX-770 150 mg twice 
daily, then VX-770 75 
mg twice daily 
 
Group 5 (n = 4) 
-Placebo twice daily, 
then placebo twice daily 
 
Part 2: 
-VX-770 150 mg twice 
daily (n = 8) 
-VX-770 250 mg twice 
daily (n = 7) 
Part 1: 
 
Nasal potential difference change from baseline to day 14: 
-VX-770 25 mg twice daily: –1.6 mV (95% CI –5.6 to 2.5; p = 
0.43) 
-VX-770 75 mg twice daily: –4.7 mV (95% CI –7.5 to –1.9; p 
=0.003) 
-VX-770 150 mg twice daily: –5.4 mV (95% CI –9.3 to –1.6; p 
= 0.01 
-Placebo: –1.7 mV (95% CI –6.1 to 2.6; p = 0.41) 
 
Mean change in sweat chloride from baseline to day 14: 
-VX-770 25 mg twice daily: –32.9 mEq/L (95% CI –42.4 to –
23.3; p < 0.001) 
-VX-770 75 mg twice daily: –40.4 mEq/L (95% CI –48.7 to –
32.2; p < 0.001) 
-VX-770 150 mg twice daily: –42.3 mEq/L (95% CI –52.8 to –
31.8; p < 0.001) 
-Placebo: –4.4 mEq/L (95% CI –10.4 to 19.1; p = 0.53) 
 
Relative change in FEV1 from baseline: 
-VX-770 25 mg twice daily: 4.9% (95% CI –2.9 to 12.5; p = 
0.18) --VX-770 75 mg twice daily: 10% (95% CI 4.5 to 15.6; p 
= 0.002) -VX-770 150 mg twice daily: 10.5% (95% CI 3.3 to 
17.7; p = 0.008) 
-Placebo: 0.7% (95% CI –8.8 to 10.2; p = 0.88) 
 
 
Part 2: 
 
Nasal potential difference change from baseline to day 28: 
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days -Placebo (n = 4) 
 
 
28 days 
-VX-770 150 mg twice daily: –3.5 mV (95% CI –8.3 to 0.5; p = 
0.02) 
-VX-770 250 mg twice daily: –5.5 mV (95% CI –28.5 to 2; p = 
0.05) 
-Placebo: –0.4 mV (95% CI –2.3 to 4; p = 0.88) 
 
Mean change in sweat chloride from baseline to day 28: 
-VX-770 150 mg twice daily: –59.5 mEq/L (95% CI –66 to –19; 
p = 0.008) 
-VX-770 250 mg twice daily: –38 mEq/L (95% CI –47 to –10.5; 
p = 0.02) 
-Placebo: 5 mEq/L (95% CI –2 to 11; p = 0.38 
 
Relative change in FEV1 from baseline: 
-VX-770 150 mg twice daily: 8.7% (95% CI 2.3 to 31.3; p = 
0.008) 
-VX-770 250 mg twice daily: 4.4% (95% CI 0 to 18.3; p = 0.03) 
-Placebo: 7.3% (95% CI 5.2 to 8.2; p = 0.13) 
 
CFQ-R median change from baseline to 28 days: 
-VX-770 150 mg twice daily: 8.3 points (95% CI 0 to 16.7; p = 
0.06) 
-VX-770 250 mg twice daily: 11.1 points (95% CI –5.6 to 33.3; 
p = 0.08) 
-Placebo: 2.8 points (95%CI –5.6 to 11.1; p = 0.75) 
 
Ramsey et 
al., 2011 
Randomized, 
double-blind, 
placebo-controlled 
 
161 pts. with CF 
Age 12-53 years 
FEV1 40%-90% 
At least 1 G551D 
Ivacaftor (VX-770) 150 
mg twice daily 
(n = 83) 
 
Placebo twice daily 
(n = 78) 
 
48 weeks 
Absolute change in FEV1 percentage from baseline at 48 
weeks (p < 0.0001): 
-VX-770: 10.1% 
-Placebo: –0.4% 
 
Mean change in sweat chloride from baseline to 48 weeks 
(p < 0.0001): 
-VX-770: –48.7 mEq/L 
-Placebo: –0.6 mEq/L 
 
Number of pulmonary exacerbations (p = 0.0003): 
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-VX-770: 28 
-Placebo: 44 
 
Weight change from baseline to 48 weeks (p < 0.0001): 
-VX-770: 3.1 kg 
-Placebo: 0.4 kg 
 
CFQ-R median change from baseline to 48 weeks (p < 
0.001): 
-VX-770: 5.9 points 
-Placebo: –2.7 points 
 
McKone et 
al., 2011 
Open-label 
extension 
 
144 pts. with CF 
who completed 
randomized phase 
III study 
 
Age 17-36 years 
FEV1 43%-90% 
At least 1 G551D 
Ivacaftor (VX-770) 150 
mg twice daily 2-60 
weeks (n = 144) 
Absolute change in FEV1 percentage from baseline: 
-2 weeks of treatment: 10.1% ± 8.4% 
-12 weeks of treatment: 10.8% ± 9.5% 
-50 weeks of treatment: 11.2% ± 9.7% 
-60 weeks of treatment: 11.1% ± 9.7% 
 
Relative change in FEV1 percentage from baseline: 
-2 weeks of treatment: 18.2% ± 17.8% 
-12 weeks of treatment: 19.9% ± 20.1% 
-50 weeks of treatment: 18.8% ± 16.1% 
-60 weeks of treatment: 18.7% ± 17% 
 
Aherns et 
al., 2011 
Randomized, 
double-blind, 
placebo-
controlled, 
multicenter 
 
52 pts. with CF 
Age 6-11 years 
FEV1 40%-105% 
At least 1 G551D 
Ivacaftor (VX-770) 150 
mg twice daily 
(n = 26) 
 
Placebo twice daily 
(n = 26) 
 
48 weeks 
Absolute change in FEV1 percentage from baseline at 24 
weeks (p < 0.0001): 
-VX-770: 12.57% 
-Placebo: 0.04% 
 
Absolute change in FEV1 percentage from baseline at 48 
weeks vs placebo (p = 0.0006): 
-VX-770: 10% (95% CI 4.5 to 15.5) 
 
Mean change in sweat chloride from baseline to 24 weeks 
(p < 0.0001): 
-VX-770: –55.53 mEq/L 
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-Placebo: –1.21 mEq/L 
 
Weight change from baseline to 24 weeks (p = 0.0004): 
-VX-770: 3.69 kg 
-Placebo: 1.79 kg 
 
Weight change from baseline to 48 weeks vs placebo (p = 
0.0002): 
-VX-770: 2.8 kg 
 
Absolute CFQ-R change from baseline to 24 weeks (p = 
0.1092): 
-VX-770: 6.31 points 
-Placebo: 0.25 points 
 
Flume et 
al., 2012 
Randomized, 
double blind, 
placebo-
controlled, parallel 
group with open-
label extension 
 
Part 1: 
 
140 pts. with CF 
 
 
Part 2: 
 
38 pts. with CF 
Age ≥12 years 
Homozygous 
F508del 
Part 1: 
 
Ivacaftor (VX-770) 150 
mg twice daily 
(n = 112) 
 
Placebo (n = 28) 
 
16 weeks of treatment 
 
 
Part 2: 
Open-label (n = 33) 
 
Ivacaftor (VX-770) 150 
mg twice daily up to 96 
weeks 
Change in FEV1 from baseline to week 16 vs placebo: 
-VX-770: 1.7% (p = 0.15) 
 
Change in FEV1 from week 16 to week 40: 
-VX-770: –3.5% ± 11.7% 
 
Change in sweat chloride from baseline to week 16 vs 
placebo: 
-VX-770: –2.9 mEq/L (p = 0.04) 
 
Change in sweat chloride from week 16 to week 40: 
-VX-770: 2.2 mEq/L ± 12.2 
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 Appendix 2. VX-809 studies (Table amended from Pettit, 2012). 
 
Reference Design Treatment Results 
Clancy et al., 
2012 
Randomized, double-
blind, placebo-controlled 
 
89 pts. with CF 
Age 18-54 years 
FEV1 ≥40% 
F508del homozygous 
 
VX-809 25 mg 
daily 
 
VX-809 50 mg 
daily 
 
VX-809 100 mg 
daily 
 
VX-809 200 mg 
daily 
 
Placebo 
 
28 days 
Number of pulmonary exacerbations (p = 0.62): 
-VX-809: 17% 
-Placebo: 12% 
 
Mean change in sweat chloride from baseline to day 
28 vs placebo: 
-VX-809 25 mg daily: 0.1 mEq/L 
-VX-809 50 mg daily: –4.61 mEq/L 
-VX-809 100 mg daily: –6.13 mEq/L (95% CI –12.25 to –
0.01; p < 0.05) 
-VX-809 200 mg daily: –8.21 mEq/L (95% CI –14.33 to –
2.1; p < 0.01) 
 
Mean change in FEV1 from baseline to day 28 (p = 
NS): 
-VX-809 25 mg daily: –2.46% 
-VX-809 50 mg daily: –2.15% 
-VX-809 100 mg daily: 0.32% 
-VX-809 200 mg daily: 0.47% 
-Placebo: 0.07% 
 
CFQ-R change from baseline to day 28: 
-VX-809 25 mg daily: –5.2 points 
-VX-809 50 mg daily: –6.3 points 
-VX-809 100 mg daily: –1.3 points 
-VX-809 200 mg daily: 2.2 points placebo: 4.5 points 
 
 
Boyle et al., 2011 Randomized, double-
blind, placebo-controlled, 
multicenter, cohort 
 
62 pts. with CF 
Part 1: 
 
VX-809 200 mg 
daily 
 
Mean change in sweat chloride from day 1 to day 14: 
 
-VX-809 200 mg daily: –4.21 mEq/L 
-Placebo: –2.86 mEq/L 
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Age >18 years 
FEV1 ≥40% 
Homozygous F508del 
Placebo 
 
14 days 
 
 
Part 2: 
 
VX-809 200 mg 
daily plus VX-770 
150 mg twice 
daily 
 
VX-809 200 mg 
daily plus VX-770 
250 mg twice 
daily 
 
Placebo 
 
7 days 
Mean change in sweat chloride from day 14 to day 28: 
-VX-809 plus VX-770 150 mg twice daily: –1.65 mEq/L 
-VX-809 plus VX-770 250 mg twice daily: –8.96 mEq/L (p 
< 0.05 vs placebo) 
-Placebo: 0.86 mEq/L 
 
Change in FEV1 percentage from day 1 to day 14: 
-VX-809 200 mg daily: –0.34% 
-Placebo: 1.73% 
 
Change in FEV1 percentage from day 14 to day 21: 
-VX-809 plus VX-770 150 mg twice daily: 3.42% (p < 0.05 
vs baseline) 
-VX-809 plus VX-770 250 mg twice daily: 0.57% placebo: 
–1.47% 
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Appendix 3. Ataluren (PTC124) studies (Table amended from Pettit, 2012). 
 
Reference Design Treatment Results 
Kerem et al., 
2008 
Randomized 
 
Cycle 1: 
 
23 pts. with CF 
 
 
Cycle2: 
 
21 pts. with CF 
 
 
Age 18-56 years 
FEV1 ≥40% 
At least 1 nonsense 
(class I) mutation 
 
Cycle 1: 
 
-Ataluren 4 mg/kg at 
breakfast, 
4 mg/kg at lunch, 8 mg/kg 
with dinner 
 
-14 days treatment, then 
14 days without treatment 
 
 
Cycle 2: 
-Ataluren 10 mg/kg at 
breakfast, 10 mg/kg at 
lunch, 20 mg/kg with 
dinner 
Mean change in nasal potential difference 
chloride transport from baseline to day 14: 
-Cycle 1: –7.1 mV ± 7 (p < 0.0001) 
 
-Cycle 2: –3.7 mV ± 7.3 (p = 0.032) 
 
 
Pts. with nasal potential difference within 
normal range: 
-Cycle 1: 13 (57%; p = 0.0003) 
 
-Cycle 2: 9 (43%; p = 0.02)  
 
 
Weight change from baseline: 
-Cycle 1: 0.6 kg ± 0.6 (p < 0.001) 
 
-Cycle 2: maintained 
 
Sermet-
Gaudelus et al., 
2010 
Randomized 
 
30 pts. with CF 
 
Age 6-18 years 
FEV1 ≥40% 
At least 1 nonsense 
(class I) mutation 
 
-Ataluren 4 mg/kg 
breakfast, 4 mg/kg at 
lunch, 8 mg/kg with dinner 
 
-Ataluren 10 mg/kg at 
breakfast, 10 mg/kg at 
lunch, 20 mg/kg with 
dinner 
 
-14 days treatment, 14 
days without treatment, 
then 14 days of the 
opposite dosing regimen 
 
Number of pts. with nasal potential difference 
change of at least –5 mV at the end of cycle 2: 
-Low-to-high dosing cohort: 8 (53%) (95% CI 30 to 
76; p < 0.0001) 
 
-High-to-low dosing cohort: 7 (47%) (95% CI 24 to 
70; p = 0.0003) 
 
 
Mean change in chloride transport from 
baseline to end of cycle 2: 
-Low-to-high dosing cohort: –4.6 mV (p = 0.037) 
 
-High-to-low dosing cohort: –3.9 mV (p = 0.046) 
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-Low-to-high cohort 
received 4 mg/kg, 4 mg/kg, 
8 mg/kg treatment regimen 
first 
 
-High-to-low cohort 
received the 10 mg/kg, 10 
mg/kg, 20 mg/kg treatment 
regimen first 
 
Wilschanski et 
al., 2011 
Randomized 
 
19 pts. with CF 
Age 19-57 years 
FEV1 ≥40% 
At least 1 nonsense 
(class I) mutation 
 
Ataluren: 
 
4 mg/kg at breakfast, 4 
mg/kg at lunch, 8 mg/kg 
with dinner 
 
OR 
 
10 mg/kg at breakfast, 10 
mg/kg at lunch, 20 mg/kg 
with dinner 
 
12 weeks 
Number of pts. with nasal potential difference 
change of at least –5 mV at end of treatment: 
-Low dose: 7 (64%) (95% CI 35 to 86; p < 0.001) 
 
-High dose: 4 (57%) (95% CI 23 to 87; p < 0.001) 
 
-Combined groups: 11 (61%) (95% CI 39 to 80; p < 
0.001) 
 
 
Mean change in chloride transport from 
baseline to end of treatment: 
-Low dose: –6.8 mV (p = 0.004) 
 
-High dose: –3.4 mV (p = 0.025) 
 
-Combined groups: –5.4 mV (p < 0.001) 
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